Results 21 to 30 of about 46,119 (273)
The pharmacogenetics of imanitib [PDF]
Genome Medicine, 2010 Imatinib mesylate (IM), a tyrosine kinase inhibitor, is one of the first molecularly targeted therapies to have been used in the clinic. It has proven to be efficient in the treatment of chronic myeloid leukemia and also in other malignancies that involve expression of a tyrosine kinase.
Dulucq, Stéphanie, Krajinovic, Maja
openaire +2 more sources
A Randomized, Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression
Journal of the American Academy of Child and Adolescent Psychiatry, 2021 Objective: Numerous commercial pharmacogenetics panels are now widely available for clinical use in psychiatric practice. However, there is a paucity of literature evaluating the use of combinatorial pharmacogenetics panels to enhance outcomes in the ...
Jennifer L. Vande Voort +8 more
semanticscholar +1 more source
Some aspects of genetics and pharmacogenetics understanding by pharmacy students in Ukraine
Egyptian Journal of Medical Human Genetics, 2015 Background: Prescription and administration of drugs are still carried out without taking into consideration the individual’s needs of a particular patient on the post-Soviet territory.
O.V. Filiptsova +2 more
doaj +1 more source
Acta Pharmaceutica Sinica B, 2022 Combination of passive targeting with active targeting is a promising approach to improve the therapeutic efficacy of nanotherapy. However, most reported polymeric systems have sizes above 100 nm, which limits effective extravasation into tumors that are
Pearl Moharil +12 more
doaj +1 more source
Moving Pharmacogenetics into Practice: It’s All About the Evidence!
Clinical pharmacology and therapy, 2021 The evidence for pharmacogenetics has grown rapidly in recent decades. However, the strength of evidence required for the clinical implementation of pharmacogenetics is highly debated.
Jasmine A. Luzum +5 more
semanticscholar +1 more source
Pharmacogenetics of osteoporosis [PDF]
Best Practice & Research Clinical Endocrinology & Metabolism, 2010 Osteoporosis is a complex bone disorder with a strong genetic basis. The genetics of osteoporosis encompasses two main areas: genetics of disease susceptibility and pharmacogenetics of drug response. The former has been widely studied in the past few decades, while the latter is still largely untouched.
MARINI, FRANCESCA, BRANDI, MARIA LUISA
openaire +8 more sources
BMC Pregnancy and Childbirth, 2017 Background Pharmacogenetics is an emerging field currently being implemented to improve safety when prescribing drugs. While many women who take drugs during pregnancy would likely benefit from such personalized drug therapy, data is lacking on the ...
Aizati N. A. Daud +7 more
doaj +1 more source
Clinical and Translational Science, 2019 Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and ...
K. Caudle +11 more
semanticscholar +1 more source
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
Frontiers in Pharmacology, 2022 Many drugs are being administered to tackle coronavirus disease 2019 (COVID-19) pandemic situations without establishing clinical effectiveness or tailoring safety.
M. Biswas +5 more
semanticscholar +1 more source
Pharmacogenetics at Scale: An Analysis of the UK Biobank
bioRxiv, 2020 Pharmacogenetics (PGx) studies the influence of genetic variation on drug response. Clinically actionable associations inform guidelines created by the Clinical Pharmacogenetics Implementation Consortium (CPIC), but the broad impact of genetic variation ...
G. McInnes +5 more
semanticscholar +1 more source